Venglustat (BioDeep_00000837671)
代谢物信息卡片
化学式: C20H24FN3O2S (389.1573176)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C1=CSC(=N1)C2=CC=C(C=C2)F)NC(=O)OC3CN4CCC3CC4
InChI: InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1
描述信息
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
同义名列表
4 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D11633
- PubChem: 60199242
- DrugBank: DB14966
- ChEMBL: CHEMBL4297611
- CAS: 1401090-53-6
- medchemexpress: HY-16743
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Catherine Viel, Jennifer Clarke, Can Kayatekin, Amy M Richards, Ming Sum R Chiang, Hyejung Park, Bing Wang, Lamya S Shihabuddin, S Pablo Sardi. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model.
Scientific reports.
2021 10; 11(1):20945. doi:
10.1038/s41598-021-00404-5. [PMID: 34686711] - M Judith Peterschmitt, Nigel P S Crawford, Sebastiaan J M Gaemers, Allena J Ji, Jyoti Sharma, Theresa T Pham. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
Clinical pharmacology in drug development.
2021 01; 10(1):86-98. doi:
10.1002/cpdd.865. [PMID: 32851809] - Einat B Vitner, Hagit Achdout, Roy Avraham, Boaz Politi, Lilach Cherry, Hadas Tamir, Yfat Yahalom-Ronen, Nir Paran, Sharon Melamed, Noam Erez, Tomer Israely. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
The Journal of biological chemistry.
2021 Jan; 296(?):100470. doi:
10.1016/j.jbc.2021.100470. [PMID: 33639165] - Karen M Ashe, Eva Budman, Dinesh S Bangari, Craig S Siegel, Jennifer B Nietupski, Bing Wang, Robert J Desnick, Ronald K Scheule, John P Leonard, Seng H Cheng, John Marshall. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Molecular medicine (Cambridge, Mass.).
2015 Apr; 21(?):389-99. doi:
10.2119/molmed.2015.00088. [PMID: 25938659]